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Insights into early stage of antibiotic
development in small- and medium-sized
enterprises: a survey of targets, costs, and
durations
Christine Årdal1* , Enrico Baraldi2, Ursula Theuretzbacher3, Kevin Outterson4, Jens Plahte5, Francesco Ciabuschi6
and John-Arne Røttingen7
Abstract
Background: Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance
continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new
incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a
greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and
medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other
drugs. This paper attempts to gather a better understanding of SMEs’ targets, costs, and durations related to
discovery and early phase development of antibacterial therapies.
Methods: DRIVE-AB, a project focused on developing new economic incentives to stimulate antibacterial innovation,
held a European stakeholder meeting in February 2015. All SMEs invited to this meeting (n = 44) were subsequently
sent a survey to gather more data regarding their areas of activity, completed and expected development costs and
timelines, and business models.
Results: Twenty-five companies responded to the survey. Respondents were primarily small companies each focusing
on developing 1 to 3 new antibiotics, focused on pathogens of public health importance. Most have not yet
completed any clinical trials. They have reported ranges of discovery and development out-of-pocket costs that appear
to be less expensive than other studies of general pharmaceutical research and development (R&D) costs. The duration
ranges reported for completing each phase of R&D are highly variable when compared to previously published
general pharmaceutical innovation average durations. However, our sample population is small and may not be fully
representative of all relevant antibiotic SMEs.
Conclusions: The data collected by this study provide important insights and estimates about R&D in European SMEs
focusing on antibiotics, which can be combined with other data to design incentives to stimulate antibacterial
innovation. The variation implies that costs and durations are difficult to generalize due to the unique characteristics of
each antibiotic project and depend on individual business strategies and circumstances.
Keywords: Antimicrobial innovation, Antibacterial innovation, DRIVE-AB, Pharmaceutical research and development
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Background
The world is facing an emerging threat of greater anti-
biotic resistance [1]. New antibacterial technologies are
needed to treat pathogens as they become increasingly
resistant to existing antibiotics [1, 2]. Yet, the last new
classes of antibiotics to meet unmet needs were discovered
in the 1980s [3, 4]. Only about five large pharmaceutical
companies invest in antibacterial research & development
(R&D) today [5]. However, many more small to medium-
sized enterprises (SMEs) have been contributing to the R&D
pipeline in this field and are currently the most significant
participants in discovery and pre-clinical development activ-
ities [6, 7]. Seven out of the eight most recently approved
antibiotics were based on key research and early develop-
ment performed at SMEs [8]. Thus SMEs are key actors in
any scheme to reinvigorate antibacterial drug innovation.
Antibacterial innovation is receiving significant polit-
ical attention of late, including in the G7 and G20
groups of countries [9], the World Health Organization
[10] and the United Nations General Assembly [11]. The
United Kingdom has provided political momentum to
increase antibacterial innovation by commissioning the
AMR Review, led by the economist, Lord Jim O’Neill, to
propose potential solutions, which were completed in
May 2016 [12]. Europe’s Innovative Medicines Initiative
(IMI) has financed a project, DRIVE-AB (i.e., Driving re-
investment in research and development for antibiotics
and advocating their responsible use, www.drive-ab.eu),
a consortium of 16 public sector partners and seven
pharmaceutical companies, which aimed to transform
the way policymakers stimulate innovation, sustainable
use and equitable access of novel antibacterial products
to meet public health needs. This article is a part of
DRIVE-AB’s research efforts.
A variety of economic incentives have been proposed
to stimulate antibacterial drug innovation [12–15]. Since
many large pharmaceutical companies have exited the
antibiotic field citing unsatisfactory commercial returns
[16], the incentives are aimed at stimulating greater pri-
vate sector involvement by increasing publicly sponsored
rewards at the time of regulatory approval so that anti-
bacterial innovation becomes an attractive business case.
Determining the appropriate reward amount is a chal-
lenging task since it needs to sway innovators and inves-
tors to increase their private investments in antibacterial
R&D while at the same time ensuring that the public
sector is receiving value for money and meeting the
important public health goals of sustainable use and
equitable access. Knowledge on R&D costs, timelines,
and profit expectations of pharmaceutical and venture
capital companies is important in order to design and
scale up effective solutions. Such knowledge about SMEs
is of particular importance, given their position as the
primary early-stage antibiotic innovators.
Actual pharmaceutical R&D costs are deemed highly
confidential and controversial. Few researchers have been
allowed access to this type of data, with the one main ex-
ception of DiMasi and colleagues at Tufts University,
whose results are based upon data from ten, large
pharmaceutical companies focusing on a range of thera-
peutic areas [17]. The study has been subject to much
debate due to a lack of transparency and the resulting
implications for pricing of pharmaceuticals [18].
This article is meant to shed some light on the targets,
costs and durations of early phase development (up to
Phase II clinical trials) for antibiotic innovation (see
Table 1) in European SMEs.
Methods
Forty-four (44) European-based SMEs were invited to at-
tend a stakeholder meeting in London in February 2015,
with a purpose to understand the environment in which
SMEs operate, their motivations, and the challenges they
face in undertaking antibiotic R&D. The list of companies
and contacts was gathered through expert advice and per-
sonal contacts of all known European SMEs with at least
one antibacterial project in their pipelines. Out of the 44
SMEs invited, representatives of twenty-six (26) compan-
ies attended the meeting. The companies varied in size,
from virtual companies with no full-time employees to
those with dozens of employees. The attendees were
divided into four groups with rapporteurs assigned to each
group. Each group followed a discussion guide which
included challenges faced by antibacterial drug-focused
SMEs, financial barriers to investment, the role of SMEs
in relation to other R&D organizations, and brainstorming
on potential incentives to address SME challenges. Find-
ings from the group work were then discussed in plenary.
A final meeting report has been produced which includes
the discussion questions, as well as the list of the attending
SMEs [19].
A survey (see Additional file 1) was sent on March 5,
2015 to these 44 antibacterial-focused SMEs to gather
more specific data regarding their areas of activity,
development costs and timelines by R&D phase, and
business models. Technology Readiness Levels (TRL)
[20] are also given in Table 1 in order to ease compari-
son of this article’s results with other articles. Reminder
e-mails were sent on April 8, 2015 and May 5, 2015.
Since the survey asks respondents to share confidential
information, such as development costs, it was decided
that the answers would be best formatted as multiple
choice ranges. The intention was to both receive an
acceptable response rate as well as to allow participants
to complete the survey in about 30 min or less. The
ranges for development costs and timelines were based
on existing studies from pharmaceutical R&D [17, 21].
Survey participants were asked to select the range that
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represented the value that it took for the company to
complete the identified R&D phase. Therefore, the results
for the clinical trials should not be viewed as a value for
completing one clinical trial but rather for finishing all of
the clinical trials that the company expects to perform for
the identified phase for their main antibacterial project.
An “antibacterial project” is the R&D surrounding one
specific antibiotic candidate or antibacterial technology.
Results
Twenty-five (25) SMEs responded to our survey (a response
rate of 57%). These can be classified mostly as small com-
panies since only one company has more than 100
employees. 54% of the respondents (n = 13) had no revenues
in 2014. 68% of the respondents (n = 17) focused on 1 to 3
internal antibacterial projects. In addition, 40% of the
respondents (n = 10) outsourced more than half of their
R&D budget to external organizations.
The stakeholder meeting identified three main sources
of discovery of companies’ antibacterial projects, either
they were discovered: (1) in an academic setting which
led to the establishment of a spin-off company, (2) inde-
pendently by an expert in this field who subsequently
formed a new company, or (3) in a large pharmaceutical
company and subsequently spun-off as an SME. 80% of
the survey respondents (n = 20) identified their own
research as the source of their lead antibacterial project.
In a separate question, 20% (n = 4) reported that they are
spin-offs from universities or research institutes and
another 20% (n = 4) spin-offs from a large, multinational
pharmaceutical companies.
Type of products and clinical targets pursued
Companies at the stakeholder meeting expressed that they
entered the antibacterial market because there are signifi-
cant public health opportunities in new antibacterial
products with little competition. Several of these stake-
holders also claimed that these opportunities are linked to
significant unmet public health needs. The research focus
of the survey respondents is largely small molecule devel-
opment, i.e., traditional antibiotics. 76% (n = 19) perform
R&D for small molecules, and 44% (n = 11) focus on anti-
bodies, adjunctive antibacterial technologies including
phage-based therapies and preventive vaccines. (Five
companies have both small molecules and adjunctive
programs.) Most companies focus solely on human health,
but 28% (n = 5) also target animal health and/or environ-
mental issues. The overwhelming majority of survey
respondents claimed that they are involved in research and
development of novel products, with 56% (n = 14) pursuing
a novel class and 20% (n = 5) a novel mode of action.
Participants at the stakeholder meeting agreed that the
increasing resistance problem is the primary market op-
portunity for antibacterial R&D, and SMEs aim, therefore,
to meet therapeutic needs caused by emerging resistance
against existing antibiotics. 44% (n = 11) of respondents
stated that the focus of their main antibacterial project is a
narrow-spectrum target and 36% (n = 9) a pathogen-
specific approach. 80% (n = 20) of respondents reported
their main antibacterial project targets, including Acineto-
bacter baumannii, Pseudomonas aeruginosa, Escherichia
coli, Klebsiella pneumoniae, Neisseria gonorrhoeae,
Clostridium difficile, and/or Staphylococcus aureus.
SMEs focused on pharmaceutical innovation typically
perform discovery and early phase development work
(up to Phase II clinical trials). SMEs at the stakeholder
meeting stated that they struggled to find an exit
strategy or pathways to commercialize their products
due to the paucity of large, pharmaceutical companies
actively pursuing R&D on antibacterial products. Many
did not see a realistic way to commercialize products by
themselves, but were considering taking on this role due
Table 1 Phases of R&D and Technology Readiness Levels (TRLs) in drug development
R&D Phase Description TRL
Research - Discovery activities,
hit generation and testing
Generation of chemical starting points (hits) from screens or other drug discovery strategies 2
Research - Lead compound
identification
Hits are evaluated and undergo limited optimization to identify promising lead compounds with
meaningful activity against the target pathogens and possess the properties needed to make an
effective and safe drug
3
Research - Lead compound
optimization
Modifying and testing lead compound series to improve compound properties; selecting a candidate
drug for further preclinical studies
4
Development - Preclinical testing Conducting required toxicity and efficacy in vitro and vivo studies under good laboratory practice
(GLP) protocols, and chemistry, manufacturing and control (CMC) studies
5
Development - Phase I clinical trials Testing the candidate drug in healthy volunteers to determine pharmacokinetics, safe dose ranges and
identify common toxicity; pharmacokinetic data feed into pharmacokinetic/ pharmacodynamic (PK/PD)
models to determine the most appropriate doses for the next phase
6
Development - Phase II clinical trials Testing the candidate drug in a small number of patients to obtain preliminary efficacy data and
more short term safety information; refining PK/PD models
7
Development - Phase III clinical trials Testing on a larger number of patients to document efficacy, determine non-inferiority activity
(or rarely superiority) and safety compared to other indicated drugs
8
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to the few commercialization options. When asked to
select among multiple exit strategies, 71% (n = 17) of re-
spondents expressed hope to be acquired, 63% (n = 15)
expressed hope to out-license their products, and only
17% (n = 4) would consider commercializing their
products on their own. This in turn translates into their
expectations on the extent of their development work.
36% (n = 9) of respondents aimed to complete Phase II
clinical trials before out-licensing or selling their main
antibacterial projects, whereas 24% (n = 6) aimed to
complete Phase I clinical trials. And 24% (n = 6) aimed
to out-license or sell prior to clinical trials.
Discovery and development costs and timelines
Respondents to the survey were asked to report discovery
and development costs concerning three stages of their
main antibacterial project – for each completed phase, the
current phase, and the next phase. They were requested
not to include opportunity cost or the costs of other can-
didate products. Therefore, the development cost should
represent the out-of-pocket cost in order to complete the
particular R&D phase for one antibacterial project. They
were also asked about the duration for each phase, both
completed and current. We were not able to measure the
important component of the quality and scope of the
work, for example whether the preclinical testing met bare
minimum standards or was more extensive in order to
better characterize the project.
The following development costs and timelines relate only
to those who reported performing R&D on small molecules
(n= 19) in order to report similar activities. Figure 1 shows
the current phase of R&D for the main antibacterial project
by the SMEs focusing on small molecules.
Lead compound identification
Eight SMEs have reported that they have completed lead
compound identification. This may seem contradictory
since 18 companies have reported that they are currently
beyond lead compound identification. We can only
presume that these ten companies either chose not to
report the data or that they acquired the main antibac-
terial project after lead compound identification had
already been performed. One company, at the time of
the survey, was currently performing lead compound
identification.
All eight companies reported that it took four years or
less, including three that reported it took a year or less.
Development costs ranged widely from € 100,001–250,000
(n= 3) to more than € 1 million (n = 3) (see Fig. 2) with the
remaining two companies falling in between these two
ranges. The company currently performing lead compound
identification at the time of the survey expected it to take in
total 6 months to one year and cost less than € 1 million.
Three out of the eight claimed that the main antibacterial
project represented a novel class and three claimed a novel
mode of action. However, neither duration nor the cost of
research seemed to have been influenced by novelty, mean-
ing that the novel products were spread across all cost and
duration ranges. Therefore, we can estimate that SMEs may
spend from € 100,001 to more than € 1,000,000 on lead
compound identification which can take as short as
6 months or as long as 4 years.
Lead compound optimization
Four companies reported that they have completed lead
compound optimization. Seven companies reported, at
the time of the survey, that they were currently perform-
ing lead compound optimization. One company, at the
time of the survey, was performing the previous R&D
phase (lead compound identification) and estimated
costs for lead compound optimization.
Among the four companies that have completed this
phase, one took less than a year, another took one to two
years, and the remaining two took two to four years.
Amongst the seven companies, at the time of the survey,
currently performing this phase, one company expects it to
take less than six months, another predicts it will take six
months to one year, four expect it to take one to two years,
and the remaining company expects two to four years.
Three out of the four companies that have completed
the phase reported the costs incurred. One reported
costs less than € 1 million and the other two companies
between € 1–5 million. Among the eight companies with
expected costs, six expected that the phase will cost
Fig. 1 Current phase of R&D for the main antibacterial project
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between € 1–5 million, whereas two others estimated
less than € 1 million. See Fig. 3 for the completed and
expected costs by number of SMEs.
Out of the twelve companies in total reporting for lead
compound optimization, seven claimed that the main
antibacterial project represented a novel class and four
claimed a novel mode of action. (The remaining com-
pany was performing R&D on a known class.) However,
neither duration nor cost seemed to be influenced by
novelty, meaning that the products described as novel
were spread across all cost and duration ranges. The ma-
jority of SMEs have spent (or plan to spend) from € 1 to
5 million on lead compound optimization which can
take as short as 6 months or as long as 4 years.
Preclinical testing
Four companies reported that they have completed pre-
clinical testing. Five companies reported, at the time of
the survey, that they were currently performing preclin-
ical testing. Seven companies, at the time of the survey,
were at the phase of lead compound optimization (be-
fore preclinical testing) and therefore estimated the costs
for preclinical testing.
Among the four companies that have completed the
phase, only three reported time durations. All took from
one to two years. Amongst the five companies, at the
time of the survey, currently performing the phase, one
expects it to take six months to one year, and the
remaining four expect it to take one to two years.
Amongst the four companies that have completed the
phase, one reported costs less than € 1 million and the
remaining three between € 1–5 million. Among the
twelve companies with expected costs (i.e., those cur-
rently performing preclinical testing or the previous
phase, lead optimization), two expect that the phase will
cost less than € 1 million, eight between € 1–5 million,
and two between € 5–10 million. See Fig. 4 for the com-
pleted and expected costs by number of SMEs.
Out of the 16 companies in total reporting for preclin-
ical testing, nine claimed that the main antibacterial pro-
ject represented a novel class and three claimed a novel
mode of action. (The remaining four companies are
performing R&D on known classes.) However, neither
duration nor cost seemed to have been influenced by
novelty, meaning that the novel products were gener-
ally spread across all cost and duration ranges. Both
two out of three of the least expensive projects (less
than € 1 million) and the two most expensive projects
(estimated to cost € 5–10 million) represent novel
classes. The shortest duration (6 months to one year)
was to complete preclinical testing for a project
related to a known class. The majority of SMEs have
spent (or plan to spend) from between € 1 and 5 million
on preclinical testing which can take approximately one to
two years.
Fig. 2 Out-of-pocket cost of lead compound identification per main antibiotic project
Fig. 3 Out-of-pocket costs of lead compound optimization – completed and expected – per main antibiotic project
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Phase I clinical trials
Six companies reported that they have completed Phase
I clinical trials. Two companies reported, at the time of
the survey, that they were currently performing Phase I
clinical trials. Five companies, at the time of the survey,
were performing the previous R&D phase (preclinical
trials) and estimated costs for Phase I clinical trials.
Among the six companies that have completed the
phase, three reported that it took six months to a year to
complete Phase I clinical trials, two reported between
one to two years, with the remaining reporting five or
more years. Amongst the two companies, at the time of
the survey, currently performing the phase, one expects
it to take less than six months and the other six months
to a year.
Among the six companies that have completed the
phase, two reported costs less than € 1 million,
three between € 1–5 million, and the remaining between
€ 10–15 million. Among the seven companies with ex-
pected costs, one expects that the phase will cost less than
€ 1 million, four between € 1–5 million, and two between
€ 5–10 million. See Fig. 5 for the completed and expected
costs by number of SMEs.
Out of the 13 companies in total reporting for Phase I
clinical trials, seven claimed that the main antibacterial
project represented a novel class and two claimed a
novel mode of action. (The remaining four represented
R&D on known classes.) However, neither duration nor
cost seemed to have been influenced by novelty, mean-
ing that the products described as novel were spread
across all cost and duration ranges. The one company
that reported a duration of five years or more is developing
a novel class. The majority of SMEs have spent (or plan to
spend) from € 1 to 10 million on Phase I clinical trials
which can take six months to two years.
Phase II clinical trials
Only one company has completed Phase II clinical trials.
In order to safeguard the anonymity of results since few
European antibacterial-related SMEs have completed
Phase II clinical trials we have combined the completed
and expected figures for Phase II. Three companies, at
the time of the survey, were performing Phase II clinical
trials, and two companies were performing Phase I
clinical trials and reported the estimated costs for Phase
II as well.
Four companies reported duration data, two reported
that it took one to two years to complete Phase II
clinical trials and the other two reported between two to
four years. Among the six companies reported cost data,
one reported costs less than € 1 million, one between
€ 1–5 million, two between € 10–20 million, and the
remaining one more than €20 million (Fig. 6).
Out of the six companies in total reporting for Phase
II clinical trials, four claimed that the main antibacterial
project represented a novel class and one claimed a
novel mode of action. (The remaining company is
performing R&D on a known class.) However, neither
duration nor cost seemed to have been influenced by
novelty, meaning that the products described as novel
Fig. 4 Out-of-pocket costs of preclinical testing – completed and expected – per main antibiotic project
Fig. 5 Out-of-pocket costs of the Phase I clinical trial program – completed and expected – per main antibiotic project
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were generally spread across all cost and duration ranges
with the notable exception that the most expensive
assertion (more than €20 million) was related to trials
for a known class. The majority of SMEs have spent (or
plan to spend) from € 1 to 20 million on Phase II clinical
trials which can take one to four years.
Discussion
The results from our stakeholder meeting and survey
provided data regarding development targets, develop-
ment costs and timelines of European antibacterial-
focused SMEs. These may not be a full representation of
antibacterial SMEs in general since the sample popula-
tion is small, and it becomes even smaller when the data
are further sub-divided by R&D phase. Additionally, our
findings report both actual and expected out-of-pocket
costs within fairly broad ranges (as indicated in each of
the previous figures). Expected costs may change over
time. However, the results provided important insights
into the therapeutic targets, R&D costs and R&D phase
durations of European SMEs operating in antibiotic
development.
DRIVE-AB and other initiatives need estimation of
cost and duration to be made in order to effectively cal-
culate adequate rewards. An “adequate” reward is one
where the publicly-sponsored reward will generate a
positive return on investment (or net present value) for
the innovator without the public sector over-paying.
Based on our results we propose the ranges in Table 2
to estimate development costs of antibiotics for SMEs.
(We state antibiotics here since these results focus solely
on small molecule R&D.) To generate these ranges, for
most values, we have selected the lowest and highest
figures reported by the majority of SMEs who claim to
be developing novel classes or modes of action. For lead
compound identification, the higher boundary value is
“more than € 1 million”. This is unfortunate since it does
not give us a definitive value as we expected the average
value to be smaller when designing the survey. There-
fore, our proposed maximum cost is taken from the
general pharmaceutical R&D cost fig. [22] which is
USD 2.5 million. (The Euro as per the current date of this
article is slightly higher than the US dollar. We have given
an equivalent in Euros since otherwise this figure appears
to give an incorrect impression of precision).
In order to give a perspective regarding our proposed
minimum and maximum costs per R&D phase we in-
clude two other studies [17, 22] which look across all
therapeutic areas (which we call “general pharmaceutical
R&D costs”) and the antibacterial-specific costs reported
by Sertkaya et al. (Table 2) [23]. Paul et al. utilized in-
dustry benchmarking data as well as internal data from
the pharmaceutical company, Eli Lilly and Company,
therefore, representing large pharmaceutical company
costs only [22]. DiMasi et al. utilized data from ten
multinational pharmaceutical companies. Sertkaya et al.
interviewed about ten experts in antibacterial drug
development and company representatives to gather
their data regarding costs, in addition to reviewing the
published literature [23]. For Phase II clinical trials
Fig. 6 Out-of-pocket costs of Phase II clinical trials – completed and expected – per main antibiotic project
Table 2 Proposed minimum and maximum out-of-pocket cost per R&D phase for SME antibiotic innovation for DRIVE-AB models
R&D Phase General Pharmaceutical R&D Costs Sertkaya et al. [23] Proposed Minimum Cost Proposed Maximum Cost
Lead compound
identification
USD 2.5 million [22] (Used general pharmaceutical cost) € 100,000 € 2.5 million
Lead compound
optimization
USD 10 million [22] (Used general pharmaceutical cost) € 1 million € 5 million
Preclinical testing USD 5 million [22] (Used general pharmaceutical cost) € 1 million € 5 million
Phase I clinical trials USD 25 million [17] USD 10 million € 1 million € 10 million
Phase II clinical trials USD 35 million [17] USD 9–16 million € 1 million € 20 million
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Sertkaya et al. estimated the cost by indication, there-
fore, a range is given [23].
Our findings suggest that SMEs expect to perform
antibacterial drug development less expensively than
large pharmaceutical companies. One interpretation is
that SMEs are leaner in structure and more cost-
effective in their R&D activities. An alternative explan-
ation may be that SMEs focus mainly on the essential
studies that are minimally required by regulatory agen-
cies for entry into limited Phase 2 studies and that they
conduct additional studies at later time points. Total
costs may be higher than those reported by SMEs here
as the company that intends to commercialize the anti-
biotic may need to back-fill missing data to get licensure.
Larger companies may include additional supporting
studies or study variables to increase confidence in study
results and reduce future risk of failure while a smaller
company might be willing to take greater risk while an-
ticipating an exit prior to regulatory approval. Recent
changes in the regulatory landscape have significantly in-
fluenced costs and duration of later phases of clinical de-
velopment with the option of abbreviated special
pathways with smaller trial sizes. SMEs may also be an-
ticipating these cost savings from regulatory changes;
however, these should mostly be related to Phase III
clinical trials which are not included in our study. Lastly,
as stated clearly throughout the paper, a large percentage
of the data is estimated amounts which may vary when
faced with real-world obstacles. While the sample com-
panies are inexperienced with performing more advanced
development work, at least some SME executives have
substantial drug development experience from previous
employment.
Table 3 estimates the durations of R&D phases for
antibiotic R&D. Again, to generate these ranges for most
values we use the higher and lower boundaries of the
values reported by the majority of the SMEs claiming to
develop either novel classes or modes of action.
Our duration ranges demonstrate a great deal of vari-
ation. The range generally contains the estimates from
both the general pharmaceutical innovation and Sertkaya
et al., with the exception of Phase I clinical trials. Indeed,
in each R&D stage, the duration and costs reported by the
surveyed companies vary by a factor of 10 or even more
(see e.g., Fig. 5, with costs ranging between €1 million and
10–15 million; or Fig. 6 with a range between 1 and over
20 million). While this large variation implies that that
our figures on costs and duration are difficult to
generalize, it also suggests that the cost and duration of
each antibiotic project depends on many specific factors,
such as scientific and technical challenges, the presence
or absence of prior data on the specific compound (or
compound family), and a range of external factors, includ-
ing an SME’s availability of funds and experienced leading
staff. This variation in durations has also been exemplified
in Deak et al., which examined all eight antibiotics ap-
proved in the U.S. from 2010 to 2015 [8].
From the stakeholder meeting’s roundtable discussion,
several instances emerged of SMEs which were obliged
to keep R&D on hold, generally during clinical trials but
also in other phases. The barriers reported to cause
delays in R&D activities include difficulty in securing
funding and partners, preparing initial public offerings,
manufacturing and quality control issues.
Regarding targets, both the stakeholder meeting and
the survey confirmed that SMEs are focusing their R&D
efforts on therapeutic needs caused by emerging resistance
against existing antibiotics.
Conclusions
In conclusion, our results indicate that SMEs seek to de-
liver antibiotic discovery, preclinical and early clinical
development at costs lower than large pharmaceutical
companies have reported in the past. Costs for Phase III
studies were not assessed. Duration appears to be highly
variable but largely in line with other estimates.
DRIVE-AB delivered its final recommendations in
January 2018. All recommendations were extensively dis-
cussed in consultations with a broad range of stakeholders
including policymakers, healthcare insurers (both national
and private), medicines regulatory authorities, SMEs,
national research funding agencies, academic research
institutions, and more. Although principally European in
focus, DRIVE-AB actively engaged stakeholders globally
Table 3 Proposed minimum and maximum durations per R&D phase for SME antibiotic innovation for DRIVE-AB models
R&D Phase General Pharmaceutical
Innovation Durations
Sertkaya et al. [23] Proposed Minimum Duration Proposed Maximum Duration
Lead compound
identification
1.5 years [22] (Used general pharmaceutical duration) 6 months 4 years
Lead compound
optimization
2 years [22] (Used general pharmaceutical duration) 6 months 4 years
Preclinical testing 1 year [22] (Used general pharmaceutical duration) 1 year 2 years
Phase I clinical trials 33 months [17] 0.9 years 6 months 2 years
Phase II clinical trials 39 months [17] 0.8–1.5 years 1 year 4 years
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to ensure that its recommendations can be integrated in a
broader context to ensure sustainable access to efficacious
antibiotics and ultimately combatting resistance.
DRIVE-AB performed a computer simulation on dif-
ferent innovation incentives and combined several esti-
mates of costs and durations such as those reviewed in
this paper in order to calculate potential profits. It was
valuable to have direct data from SMEs in order to
develop realistic reward models. Despite the abovemen-
tioned limitations, the findings in this paper provide fur-
ther insights that can help devising more precise policy
tools for simulating pharmaceutical innovation taking
into account their costs and durations. Similar research
regarding SMEs outside of Europe would be beneficial.
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Additional file 1: Survey for SMEs. (PDF 447 kb)
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